Related Experiment Video

Updated: Jun 22, 2026

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:12

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

Vascular pharmacotherapy and dementia

Olivier Piguet1, Brett Garner

  • 1Prince of Wales Medical Research Institute, Randwick NSW 2031, Australia.

Current Vascular Pharmacology
|June 3, 2009
PubMed

Insights

Vascular disease is linked to dementia and Alzheimer's disease (AD). This review examines how treating cardiovascular risk factors may help prevent or treat dementia.

Area of Science:

  • Neurology
  • Gerontology
  • Cardiovascular Medicine

Background:

  • The global population is aging, leading to a significant increase in dementia incidence.
  • Growing evidence links vascular disease to cognitive decline and Alzheimer's disease (AD).
  • Cardiovascular risk factors like hypertension and diabetes are implicated in dementia development.

Purpose of the Study:

  • To review recent advancements connecting vascular disease and dementia, with a focus on AD.
  • To evaluate the effectiveness of vascular pharmacotherapy in dementia treatment.
  • To explore potential preventative strategies targeting vascular health.

Main Methods:

  • Literature review of recent scientific publications.
  • Analysis of studies on vascular disease and cognitive impairment.
  • Examination of clinical trial data on pharmacotherapy for dementia.

Main Results:

  • Vascular factors significantly contribute to cognitive decline and AD.
  • Pharmacological interventions targeting cardiovascular risk factors show potential.
  • Further research is needed to confirm treatment efficacy.

Conclusions:

  • Vascular health is critical for maintaining cognitive function.
  • Targeting vascular risk factors may offer a viable strategy for dementia prevention and treatment.
  • Pharmacotherapy for vascular conditions warrants further investigation for its role in managing dementia.

More Related Videos

Using Retinal Imaging to Study Dementia09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...